Defining pretomanid critical concentration (CC) for phenotypic drug-susceptibility testing (DST) methods

Name: Defining pretomanid critical concentration (CC) for phenotypic drug-susceptibility testing (DST) methods
Start: 2022-12-01T09:00:00+01:00
End: 2022-12-02T17:30:00+01:00
Location: Geneva International Conference Centre (CICG)

1–2 Dec 2022

Geneva International Conference Centre (CICG)

Europe/Zurich timezone

Overview
Registration

Administrative Support: Lou Maureen Comia

comial@who.int

Meeting objective:

To review evidence (published and unpublished) on minimal inhibitory concentrations (MICs) to determine the ECOFF(s), assess the association of the ECOFF(s) with clinical outcome data (where available) and lineage in order to define pretomanid CC for MGIT, 7H10, 7H11, LJ methods.

Starts 1 Dec 2022, 09:00

Ends 2 Dec 2022, 17:30

Europe/Zurich

In-Person

Geneva International Conference Centre (CICG), Geneva, Switzerland

17 rue de Varembe 1211 Geneva

Concept note.docx

Registration

Registration for this event is currently open.

Choose timezone

Defining pretomanid critical concentration (CC) for phenotypic drug-susceptibility testing (DST) methods

Administrative Support: Lou Maureen Comia

Meeting objective:

To review evidence (published and unpublished) on minimal inhibitory concentrations (MICs) to determine the ECOFF(s), assess the association of the ECOFF(s) with clinical outcome data (where available) and lineage in order to define pretomanid CC for MGIT, 7H10, 7H11, LJ methods.